Development and Optimization of Solid Lipid Nanoparticle for Topical Delivery
The aim of present work was to develop and evaluate solid lipid nanoparticle (SLNs) based gel for topical delivery of anti-inflammatory drug. Material and method Nabumetone loaded SLNs were developed by hot homogenization followed by ultra- sonication technique using compritol 888 ATO as solid lipid and tween 80 as a surfactant. Developed SLNs were evaluated for particle size, entrapment efficiency (EE) and drug release profile. Process and formulation parameters were optimized. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies were carried out on SLNs to mark the change in the drug and lipid modification. The Nabumetone based gels were prepared using carbopol 940 as gelling agent. Results and conclusion: The F14 batch had shown maximum entrapment efficiency up to 94.40 and sustained drug release for more than 7 hours. The particle size of optimized batch (F14) was found to be 16.54.
Keywords: Solid lipid nanoparticle, Entrapment efficiency, Colloidal carrier.
2 .Waugh A., Grant A., Anatomy and Physiology in Health and Illness, Churchill Livingstone, 9th edition, 362-366.
3. Harsh Mohan, Textbook of Pathology, Jaypee Brothers Medical Publisher (P) Ltd New Delhi, 5th edition, 802- 804.
4. Semerano, L.; Minichiello, E.; Bessis, N.; Boissier, M.C. Novel Immunotherapeutic Avenues for Rheumatoid Arthritis. Trends Mol. Med. 2016, 22, 214–229
5. McInnes, I.B.; Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 2011, 365, 2205–2219.
6. Scott D., Wolfe F., Huizinga T., Rheumatoid Arthritis. Lancet. 2010; 376(9746):1094–1108.
7. Gibofsky Allan. Epidemiology, Pathophysiology, and Diagnosis of Rheumatoid Arthritis: A Synopsis. Am J Manag Care. 2014;20:S128-S135.
8. Vivian P., Bykerk., PoonehAkhavan., Glen S. Hazlewood. Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drug Journal of Rheumatology. -2011.Vol 38, 1-24.
9. Rainer H., Müller., KarstenMader., Sven Gohla. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. -2000. Vol 50,161-177.
10. Sadiq A, Alla A, Rassol A, Formulation and Evaluation of silbinin loaded solid lipid nanoparticles for peroral use targeting lower part of gastrointestinal tract, Int J of Pharm and Pharm sci, 2014;6(1):55-67.
11. Ekambaram P, Sathali A Formulation and Evaluation of Solid Lipid Nanoparticles of Ramipril, J Young Pharmacist, 2011; 3:216-20.
12. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. Eur J Pharm Biopharm 2000; 50:161-77.
13. Luo Y, Chen D, Ren L, Zhao X, Qin J. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release 2006; 114:53-9.
14. Abdelbary G, Fahmy RH. Diazepam – loaded solid lipid nanoparticles: Design and characterization. AAPS PharmSciTech 2009;10:211-9.
15. Heinzelmann ME, Wiesendanger R. Scanning tunneling microscopy II surface science. Newyork: Springer verlogg; 1992. P. 99-149.
16. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded dolid lipid nanoparticles for topical delivery. AAPSPharmSciTech 2009; 10:289-96.
17. Cavalli R, Marengo E, Rodriguez L, Gasco MR. Effects of some experimental factors on the production process of solid lipid nanoparticles. Eur J Pharm Biopharm. 1996; 43:110–5.
18. Winter CA, Porter CC. Effect of alteration in sidechains upon anti-inflammatory and liver glycogenactivities in hydrocortisone ester. J Am Pharmacol Soc. 1957; 46:515-9.
19. Di Rosa M, Giroud JP, Willoughby DA. Studies onthe mediators of the acute inflammatory responseinduced in rats in different sites by carrageenan and turpentine. J Pathol. 1971; 104:15-29.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).